Corcept Therapeutics (CORT)

Nasdaq Health Care Pharmaceuticals S&P MidCap 400S&P SmallCap 600

$72.77

+1.14 (+1.59%)

Close of Nov 06, 2026 · end-of-day data

Source: Corcept Therapeutics's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 04, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$81.32M	$159.20M	$251.25M	$306.49M	$353.87M	$365.98M	$401.86M	$482.38M	$675.04M	$761.41M
Cost of revenue	$2.06M	$3.55M	$5.21M	$5.50M	$5.58M	$5.28M	$5.38M	$6.48M	$10.88M	$12.98M
Gross profit	$79.26M	$155.65M	$246.03M	$300.98M	$348.29M	$360.70M	$396.47M	$475.89M	$664.16M	$748.43M
Research & development	$23.84M	$40.38M	$75.25M	$89.02M	$114.76M	$113.86M	$130.99M	$184.35M	$246.89M	$254.91M
Selling, general & admin	$45.24M	$62.42M	$81.29M	$100.36M	$105.33M	$122.36M	$152.85M	$184.26M	$280.32M	$448.73M
Operating income	$10.18M	$52.85M	$89.50M	$111.61M	$128.20M	$124.48M	$112.63M	$107.28M	$136.95M	$44.80M
Pre-tax income	$8.14M	$52.81M	$92.15M	$116.68M	$131.60M	$125.01M	$116.19M	$124.56M	$161.49M	$66.46M
Income tax	$0	-$76.32M	$16.74M	$22.50M	$25.59M	$12.49M	$14.77M	$18.42M	$20.28M	-$33.19M
Net income	$8.14M	$129.12M	$75.41M	$94.18M	$106.01M	$112.51M	$101.42M	$106.14M	$141.21M	$99.65M
EBITDA	$10.27M	$52.96M	$89.73M	$112.31M	$128.73M	$125.55M	$113.89M	$108.32M	$137.75M	$45.95M
EPS (basic)	$0.07	$1.14	$0.65	$0.82	$0.92	$0.97	$0.95	$1.02	$1.35	$0.95
EPS (diluted)	$0.07	$1.04	$0.60	$0.77	$0.85	$0.89	$0.87	$0.94	$1.23	$0.82
Diluted shares	116.14M	124.52M	126.69M	122.57M	124.19M	125.96M	115.97M	111.74M	113.48M	119.99M
Gross margin	97.5%	97.8%	97.9%	98.2%	98.4%	98.6%	98.7%	98.7%	98.4%	98.3%
Operating margin	12.5%	33.2%	35.6%	36.4%	36.2%	34.0%	28.0%	22.2%	20.3%	5.9%
Net margin	10.0%	81.1%	30.0%	30.7%	30.0%	30.7%	25.2%	22.0%	20.9%	13.1%

Balance sheet

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$51.54M	$31.06M	$41.62M	$31.27M	$76.19M	$77.62M	$66.33M	$135.55M	$127.67M	$120.50M
Short-term investments	$0	$57.68M	$165.13M	$244.69M	$364.51M	$145.92M	$365.34M	$232.67M	$255.67M	$251.66M
Receivables	$9.86M	$15.30M	$17.59M	$19.93M	$26.20M	$27.62M	$31.06M	$41.12M	$53.98M	$59.79M
Inventory	$2.33M	$4.58M	$4.73M	$5.42M	$4.91M	$4.99M	$6.10M	$7.73M	$12.41M	$12.87M
Total current assets	$65.69M	$124.19M	$236.82M	$307.36M	$478.50M	$266.46M	$499.25M	$458.64M	$471.60M	$485.46M
Total assets	$68.75M	$220.54M	$311.69M	$412.31M	$571.73M	$423.76M	$583.43M	$621.52M	$840.55M	$836.65M
Total current liabilities	$27.37M	$29.57M	$35.57M	$38.84M	$47.49M	$47.54M	$72.49M	$104.50M	$140.77M	$166.09M
Short-term debt	$14.66M	$0	—	—	—	—	—	—	—	—
Long-term debt	$0	$0	—	—	—	—	—	—	—	—
Total debt	$14.66M	$0	—	—	—	—	—	—	—	—
Total liabilities	$27.37M	$29.57M	$35.81M	$41.13M	$48.39M	$47.95M	$81.59M	$114.81M	$160.96M	$188.85M
Shareholders' equity	$41.38M	$190.97M	$275.88M	$371.18M	$523.34M	$375.81M	$501.84M	$506.70M	$679.59M	$647.80M

Cash flow

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	$18.39M	$60.94M	$115.67M	$136.12M	$151.97M	$167.89M	$120.32M	$126.68M	$198.29M	$142.00M
Capital expenditures	$194.00K	$419.00K	$298.00K	$1.09M	$1.24M	$469.00K	$413.00K	$139.00K	$2.17M	$211.00K
Free cash flow	$18.20M	$60.52M	$115.37M	$135.03M	$150.73M	$167.42M	$119.91M	$126.54M	$196.12M	$141.78M
Investing cash flow	-$194.00K	-$73.46M	-$90.77M	-$117.83M	-$119.26M	$136.13M	-$114.33M	$90.91M	-$177.60M	$69.76M
Financing cash flow	-$7.10M	-$7.95M	-$14.34M	-$28.64M	$12.21M	-$302.59M	-$17.28M	-$148.72M	-$28.35M	-$220.37M
Share buybacks	$0	$0	$23.66M	$30.98M	$9.95M	—	$0	$0	$15.66M	$172.91M
Stock-based compensation	$7.06M	$13.36M	$23.75M	$29.31M	$33.54M	$42.93M	$42.44M	$48.94M	$61.35M	$84.50M
Depreciation & amortization	$87.00K	$106.00K	$236.00K	$703.00K	$525.00K	$1.07M	$1.26M	$1.04M	$795.00K	$1.15M

Income statement

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	$135.41M	$146.81M	$163.80M	$182.55M	$181.89M	$157.21M	$194.43M	$207.64M	$202.12M	$164.90M	$256.15M	$340.47M
Cost of revenue	$1.88M	$2.54M	$2.52M	$2.87M	$2.96M	$2.40M	$3.43M	$4.60M	$2.54M	$2.88M	$4.06M	$4.61M
Gross profit	$133.53M	$144.27M	$161.27M	$179.68M	$178.93M	$154.81M	$191.00M	$203.04M	$199.58M	$162.02M	$252.09M	$335.86M
Research & development	$54.71M	$58.51M	$58.74M	$59.34M	$70.30M	$60.73M	$60.47M	$68.85M	$64.86M	$66.27M	$53.89M	$56.71M
Selling, general & admin	$47.15M	$56.27M	$66.94M	$73.75M	$83.37M	$90.66M	$103.85M	$123.98M	$130.24M	$145.36M	$156.90M	$164.43M
Operating income	$31.67M	$29.50M	$35.59M	$46.60M	$25.26M	$3.42M	$26.68M	$10.22M	$4.49M	-$49.60M	$41.30M	$114.72M
Pre-tax income	$36.81M	$34.99M	$41.60M	$52.94M	$31.96M	$9.62M	$31.69M	$15.24M	$9.91M	-$44.72M	$45.93M	$120.31M
Income tax	$5.45M	$7.23M	$6.11M	$5.73M	$1.21M	-$10.93M	-$3.46M	-$4.42M	-$14.38M	-$12.95M	$2.94M	-$6.47M
Net income	$31.36M	$27.76M	$35.49M	$47.21M	$30.75M	$20.55M	$35.15M	$19.67M	$24.29M	-$31.76M	$42.99M	$126.78M
EBITDA	$31.88M	$29.62M	$35.67M	$46.92M	$25.54M	$3.88M	$27.14M	$10.70M	$4.23M	-$49.00M	$42.16M	$115.75M
EPS (basic)	$0.30	$0.27	$0.34	$0.45	$0.29	$0.19	$0.33	$0.19	$0.24	$-0.30	$0.40	$1.17
EPS (diluted)	$0.28	$0.25	$0.32	$0.41	$0.25	$0.17	$0.29	$0.16	$0.20	$-0.30	$0.36	$1.01
Diluted shares	-312.00K	109.92M	111.24M	113.72M	1.91M	119.82M	120.48M	119.44M	6.00K	104.44M	118.39M	123.20M
Gross margin	98.6%	98.3%	98.5%	98.4%	98.4%	98.5%	98.2%	97.8%	98.7%	98.3%	98.4%	98.6%
Operating margin	23.4%	20.1%	21.7%	25.5%	13.9%	2.2%	13.7%	4.9%	2.2%	-30.1%	16.1%	33.7%
Net margin	23.2%	18.9%	21.7%	25.9%	16.9%	13.1%	18.1%	9.5%	12.0%	-19.3%	16.8%	37.2%

Balance sheet

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Cash & equivalents	$135.55M	$149.75M	$128.59M	$137.29M	$127.67M	$89.82M	$102.75M	$125.14M	$120.50M	$108.74M	$111.04M	$98.72M
Short-term investments	$232.67M	$261.01M	$344.57M	$243.05M	$255.67M	$232.94M	$239.48M	$296.55M	$251.66M	$229.45M	$197.16M	$271.98M
Receivables	$41.12M	$61.52M	$53.84M	$59.72M	$53.98M	$61.82M	$64.57M	$69.63M	$59.79M	$39.07M	$76.92M	$111.06M
Inventory	$7.73M	$7.19M	$8.35M	$8.05M	$12.41M	$14.37M	$12.28M	$12.35M	$12.87M	$12.89M	$13.19M	$11.91M
Total current assets	$458.64M	$503.37M	$560.85M	$466.98M	$471.60M	$438.50M	$443.11M	$541.13M	$485.46M	$426.03M	$439.68M	$533.87M
Total assets	$621.52M	$655.93M	$714.55M	$784.26M	$840.55M	$846.46M	$801.72M	$823.61M	$836.65M	$814.88M	$888.70M	$1.03B
Total current liabilities	$104.50M	$97.20M	$100.75M	$126.22M	$140.77M	$143.07M	$144.66M	$172.26M	$166.09M	$149.19M	$153.80M	$177.68M
Total liabilities	$114.81M	$108.07M	$118.31M	$145.42M	$160.96M	$163.17M	$165.93M	$191.71M	$188.85M	$176.89M	$182.93M	$200.29M
Shareholders' equity	$506.70M	$547.86M	$596.24M	$638.84M	$679.59M	$683.28M	$635.79M	$631.90M	$647.80M	$637.99M	$705.78M	$833.74M

Cash flow

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Operating cash flow	$5.53M	$23.76M	$41.19M	$73.29M	$60.06M	$4.77M	$44.30M	$54.48M	$38.45M	-$16.77M	$33.54M	$142.89M
Capital expenditures	$0	$0	$416.00K	$1.64M	$121.00K	$104.00K	$57.00K	$0	$50.00K	$201.00K	$2.53M	$709.00K
Free cash flow	$5.53M	$23.76M	$40.77M	$71.66M	$59.94M	$4.67M	$44.24M	$54.48M	$38.40M	-$16.97M	$31.02M	$142.18M
Investing cash flow	$17.10M	-$9.01M	-$60.19M	-$44.04M	-$64.36M	-$3.17M	$70.13M	$14.64M	-$11.84M	$4.54M	-$29.24M	-$131.99M
Financing cash flow	$766.00K	-$543.00K	-$2.15M	-$21.09M	-$4.56M	-$39.80M	-$102.93M	-$46.41M	-$31.22M	$760.00K	-$2.04M	-$23.89M
Share buybacks	$0	$476.00K	$3.48M	$11.71M	$0	$27.43M	$103.02M	$42.46M	$0	$0	$0	$5.75M
Stock-based compensation	$13.06M	$13.25M	$15.21M	$16.10M	$16.80M	$21.83M	$19.02M	$22.88M	$20.77M	$23.04M	$29.42M	$29.44M
Depreciation & amortization	$214.00K	$120.00K	$76.00K	$318.00K	$281.00K	$462.00K	$469.00K	$477.00K	-$259.00K	$598.00K	$863.00K	$1.03M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.